The National Institutes of Health awarded nearly $470 million to build a national study population of diverse research volunteers and support large-scale studies on the long-term effects of COVID-19. The NIH Researching COVID to Enhance Recovery (RECOVER) Initiative made the parent award to New York University (NYU) Langone Health, New York City,...
A small study found that young adults with heritable forms of hypertrophic cardiomyopathy who received valsartan, a drug used to treat high blood pressure and heart failure, tolerated the treatment and were less likely to experience changes in cardiovascular structure and function.
After studying lung infection rates among New York City firefighters who served as first responders at the World Trade Center on Sept. 11, 2001 and were exposed to tiny air pollution particles, researchers identified factors that overlapped with lung infection risks.
A phase 3 trial found using colchicine reduced death and hospitalization rates among adults with COVID-19 recovering at home, but only if they had a positive test result. More research is necessary to assess the benefits of using this anti-inflammatory treatment for moderate COVID-19 cases.
A phase 2 study with 59 patients found fostamatinib, a targeted immune therapy used for a rare bleeding disorder, did not result in more adverse outcomes among adults hospitalized for COVID-19 who required assisted breathing support.
After following more than 123,000 women, ages 50-79, for 15 years, researchers found that those who ate a higher proportion of plant-based foods with healthful fats had a reduced risk for cardiovascular disease, coronary heart disease, and heart failure.